[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Takeshita Y, Takamura T, Minato H, Misu H, Ando H, Yamashita T, Ikeda H, Nakanuma Y, Kaneko S: Transformation of p53-positive papillary thyroid carcinoma to anaplastic carcinoma of the liver following postoperative radioactive iodine-131 therapy. Intern Med; 2008;47(19):1709-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of p53-positive papillary thyroid carcinoma to anaplastic carcinoma of the liver following postoperative radioactive iodine-131 therapy.
  • Multiple liver metastases were incidentally detected in the lobe of the liver of an 81-year-old woman following total thyroidectomy and ablative radioactive iodine administration for the treatment of papillary thyroid carcinoma.
  • A biopsy specimen taken from the metastatic liver tumor was histologically diagnosed as anaplastic carcinoma.
  • Immunohistochemical staining for p53 was positive in both the primary tumor and liver biopsy specimens.
  • We considered this to have been caused by anaplastic transformation from papillary thyroid carcinoma during treatment.
  • We report a rare case of multiple liver metastases from a papillary thyroid carcinoma, which we believe to be the result of anaplastic transformation during postoperative radioactive iodine-131 therapy.
  • [MeSH-major] Carcinoma, Papillary / metabolism. Carcinoma, Papillary / radiotherapy. Iodine Radioisotopes / adverse effects. Liver Neoplasms / secondary. Thyroid Neoplasms / metabolism. Thyroid Neoplasms / radiography. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827421.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


2. Kohli PS, Soni NK: Nasal tip metastasis: an unusual site and mode of spread in anaplastic thyroid carcinoma. Indian J Otolaryngol Head Neck Surg; 2008 Sep;60(3):269-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal tip metastasis: an unusual site and mode of spread in anaplastic thyroid carcinoma.
  • Anaplastic thyroid carcinoma (ATC) is the most aggressive and lethal form of thyroid malignancy which is difficult to treat.
  • At the time of diagnosis, majority of patients have distant metastases most commonly in lung, bone, and liver.
  • Implantation of malignant cells on nasal tip is also unknown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1990 Jan;22(1):19-26 [2298962.001]
  • [Cites] Surg Gynecol Obstet. 1971 Oct;133(4):673-7 [4938079.001]
  • [Cites] Otolaryngol Head Neck Surg. 1997 Jul;117(1):139 [9230343.001]
  • [Cites] Can J Surg. 2002 Jun;45(3):224-5 [12067183.001]
  • (PMID = 23120560.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450640
  • [Keywords] NOTNLM ; Implantation metastasis / Nasal metastasis / Thyroid carcinoma
  •  go-up   go-down


3. Wang CH, Shen YC, Hsieh JJ, Yeh KY, Chang JW: Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line. J Endocrinol; 2006 Aug;190(2):415-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clodronate alleviates cachexia and prolongs survival in nude mice xenografted with an anaplastic thyroid carcinoma cell line.
  • Cancer cachexia is one of the most common manifestations of advanced malignant disease and is frequently associated with decreased survival.
  • Previously, we reported the establishment of a new anaplastic thyroid carcinoma cell line, Thena, and its mouse xenograft, Thena-Nu, which induced cachexia in athymic nude mice.
  • Liver necrosis, observed in tumor-bearing mice, was also improved following clodronate treatment.
  • [MeSH-major] Cachexia / drug therapy. Carcinoma / drug therapy. Clodronic Acid / therapeutic use. Diphosphonates / therapeutic use. Thyroid Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Tumor. Cell Proliferation / drug effects. Enzyme-Linked Immunosorbent Assay / methods. Granulocyte Colony-Stimulating Factor / analysis. Interleukin-6 / analysis. Leukemia Inhibitory Factor. Liver / pathology. Mice. Mice, Inbred BALB C. Mice, Nude. Necrosis. Neoplasm Transplantation. Transplantation, Heterologous. Tumor Necrosis Factor-alpha / analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16899574.001).
  • [ISSN] 0022-0795
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Interleukin-6; 0 / Leukemia Inhibitory Factor; 0 / Lif protein, mouse; 0 / Tumor Necrosis Factor-alpha; 0813BZ6866 / Clodronic Acid; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


Advertisement
4. Sawai H, Okada Y, Funahashi H, Matsuo Y, Takeyama H, Manabe T: Anaplastic carcinoma of the pancreas with squamous features: report of a case and immunohistochemical study. Med Sci Monit; 2005 Nov;11(11):CS65-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma of the pancreas with squamous features: report of a case and immunohistochemical study.
  • BACKGROUND: Anaplastic carcinomas of the pancreas are rare aggressive tumors with survival measurable in weeks.
  • Many terms have been applied used to describe these tumors, and anaplastic foci are identified in ductal adenocarcinomas and in ectopic pancreata, but are not the dominant pattern of growth.
  • We herein present our experience with a case of anaplastic carcinoma of the pancreas with squamous features in order that allowed us to delineate the clinicopathologic and immunohistochemical features of this rare entity.
  • CASE REPORT: According to imaging findings, the 77-year-old Japanese man was diagnosed as the malignant pancreatic tumor, and underwent a surgical resection.
  • Histopathologically, anaplastic tumor cells showed focal ductal and squamous features infiltrated into pancreatic parenchyma, extrapancreatic fatty tissue, and stomach.
  • However, the patient suffered from peritonitis carcinomatosa and re-increases of multiple liver metastases, and he died in the fourteenth month after surgery.
  • CONCLUSIONS: Our immunohistochemical studies suggested that the prognosis of the case with anaplastic carcinoma presented here would be poor, due to the strong expression of integrins and IL-1RI.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Integrins / analysis. Pancreatic Neoplasms / diagnosis. Receptors, Interleukin-1 / analysis
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / diagnosis. Fatal Outcome. Humans. Immunohistochemistry. Male. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258403.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrins; 0 / Receptors, Interleukin-1
  •  go-up   go-down


5. Gotohda N, Nakagohri T, Saito N, Ono M, Sugito M, Ito M, Inoue K, Oda T, Takahashi S, Kinoshita T: A case of anaplastic ductal carcinoma of the pancreas with production of granulocyte-colony stimulating factor. Hepatogastroenterology; 2006 Nov-Dec;53(72):957-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of anaplastic ductal carcinoma of the pancreas with production of granulocyte-colony stimulating factor.
  • We report a case of anaplastic ductal carcinoma of the pancreas with production of granulocytecolony stimulating factor in a 46-year-old man.
  • Histological examination showed anaplastic ductal carcinoma (giant cell type) of the pancreas.
  • However, three months after the operation, multiple liver metastases were demonstrated by CT scan and the peripheral leukocyte count rose to 81,800/microL.
  • Anaplastic ductal carcinoma of the pancreas with production of granulocyte-colony stimulating factor is very rare.
  • Tumors with production of granulocyte-colony stimulating factor are highly malignant, and this patient died of hepatic failure four months after the operation.
  • [MeSH-major] Carcinoma, Ductal / metabolism. Carcinoma, Ductal / surgery. Granulocyte Colony-Stimulating Factor / metabolism. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Fatal Outcome. Gastrectomy. Humans. Leukocyte Count. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Male. Middle Aged. Pancreatectomy. Splenectomy. Stomach Neoplasms / secondary. Stomach Neoplasms / surgery. Tomography Scanners, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17153462.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


6. Adamidou A, Kotsaftis P, Vlachou M, Haritanti A, Xanthakis I, Zantidis A, Ntaios G: Solitary large hepatic metastasis in an elderly patient with anaplastic thyroid carcinoma: a case report. Cases J; 2009;2(1):41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary large hepatic metastasis in an elderly patient with anaplastic thyroid carcinoma: a case report.
  • BACKGROUND: We present the case of a patient who presented with anaplastic thyroid carcinoma with a solitary large liver metastasis.
  • Hepatic metastases are extremely rare in anaplastic thyroid carcinoma.
  • On physical examination, the thyroid was hard and tender on palpation and a liver mass was palpable.
  • The findings of fine-needle aspiration biopsy of the thyroid were consistent with anaplastic carcinoma.
  • Liver biopsy showed infiltrations by poorly differentiated anaplastic cells, few of which were slightly positive for thyroglobulin.
  • These findings were suggestive of a hepatic metastasis originating from anaplastic thyroid carcinoma.
  • CONCLUSION: Solitary, large hepatic metastasis may constitute a rare complication in anaplastic thyroid carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):453-64 [16474910.001]
  • [Cites] Cancer. 1978 Jun;41(6):2267-75 [657091.001]
  • [Cites] Am J Surg. 1999 Apr;177(4):337-9 [10326855.001]
  • (PMID = 19138396.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2632615
  •  go-up   go-down


7. Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA, Chen N, Szalay AA, Fong Y, Wong RJ: Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab; 2008 Nov;93(11):4403-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo.
  • CONTEXT: Anaplastic thyroid carcinoma (ATC) is a fatal disease with a median survival of only 6 months.
  • We assessed the utility of GLV-1h68 in treating anaplastic thyroid cancer in vivo.
  • At d 10, tumor viral recovery was increased more than 50-fold as compared with the injected dose, and minimal virus was recovered from the lung, liver, brain, heart, spleen, and kidneys.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Carcinoma / immunology. Thyroid Neoplasms / immunology. Vaccinia virus / immunology. Viral Vaccines / therapeutic use
  • [MeSH-minor] Animals. Cell Division / drug effects. Cell Line, Tumor. Genetic Markers. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Transplantation, Heterologous. Viral Plaque Assay

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thyroid. 2000 Jul;10(7):587-94 [10958311.001]
  • [Cites] Surgery. 2001 Dec;130(6):1028-34 [11742333.001]
  • [Cites] Surgery. 2002 Mar;131(3):245-8 [11894027.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1848-53 [12085174.001]
  • [Cites] Nat Biotechnol. 2004 Mar;22(3):313-20 [14990953.001]
  • [Cites] Expert Opin Biol Ther. 2004 Aug;4(8):1307-21 [15268664.001]
  • [Cites] World J Surg. 1998 Jul;22(7):725-30 [9606289.001]
  • [Cites] Lancet. 1973 Mar 24;1(7804):656-9 [4121857.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2155-60 [3902203.001]
  • [Cites] J Endocrinol Invest. 1991 Jun;14(6):475-80 [1723086.001]
  • [Cites] Surgery. 2007 Dec;142(6):976-83; discussion 976-83 [18063085.001]
  • [Cites] Mol Ther. 2005 Feb;11(2):180-95 [15668130.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):10038-46 [17942938.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):525-32 [15382081.001]
  • (PMID = 18697871.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009685
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Genetic Markers; 0 / Viral Vaccines
  • [Other-IDs] NLM/ PMC3728375
  •  go-up   go-down


8. Nahari D, Satchi-Fainaro R, Chen M, Mitchell I, Task LB, Liu Z, Kihneman J, Carroll AB, Terada LS, Nwariaku FE: Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer. Mol Cancer Ther; 2007 Apr;6(4):1329-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer.
  • Anaplastic thyroid carcinoma is an aggressive form of cancer with no treatment.
  • Our goals were to determine the effect of TNP-470 on anaplastic thyroid cancer using an orthotopic murine model, to identify the molecular pathways of TNP-470 actions on endothelial cells, and to determine the non-endothelial tumor effects of TNP-470.
  • We injected human anaplastic thyroid carcinoma cells (DRO'90) into the thyroid glands of nude mice.
  • TNP-470 prolonged survival and reduced liver metastases.
  • TNP-470 had direct cytotoxic effects on anaplastic thyroid carcinoma cells in vitro and in vivo.

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431111.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL061897; United States / NHLBI NIH HHS / HL / R01 HL067256; United States / NIGMS NIH HHS / GM / R01 GM067674-01A1; United States / NHLBI NIH HHS / HL / R01-HL61897; United States / NHLBI NIH HHS / HL / R01-HL67256; United States / NIGMS NIH HHS / GM / R01 GM067674
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cyclohexanes; 0 / Sesquiterpenes; 0 / Vascular Endothelial Growth Factor A; 129298-91-5 / O-(chloroacetylcarbamoyl)fumagillol; EC 3.6.5.2 / rac GTP-Binding Proteins
  •  go-up   go-down


9. Xu J, Filetti S, Hershman JM: Expression of hepatocyte nuclear factor-1alpha mRNA in human anaplastic thyroid cancer cell lines and tumors. Thyroid; 2008 May;18(5):533-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte nuclear factor-1alpha mRNA in human anaplastic thyroid cancer cell lines and tumors.
  • BACKGROUND: Hepatocyte nuclear factor (HNF)-1alpha and HNF-1beta are related transcription factors that are mainly expressed in liver cells.
  • The objective of this study was to determine whether HNF-1alpha is expressed in dedifferentiated anaplastic thyroid cancer cells.
  • METHODS: Total RNA isolated from six anaplastic thyroid cancer cell lines and 38 surgical samples was analyzed for HNF-1alpha mRNA by conventional reverse-transcription polymerase chain reaction (RT-PCR) or real-time RT-PCR.
  • RESULTS: HNF-1alpha mRNA was expressed in four of the six anaplastic cell lines.
  • HNF-1alpha transcripts were also detected in five out of six anaplastic tumors, but not in the papillary tumors except one with weak PCR signal.
  • CONCLUSION: HNF-1alpha mRNA was detected in high frequency in anaplastic thyroid cancer cell lines and tumors.
  • HNF-1alpha might play a role in the pathogenesis of anaplastic thyroid cancer.
  • [MeSH-major] Carcinoma / metabolism. Carcinoma, Papillary / metabolism. Hepatocyte Nuclear Factor 1-alpha / metabolism. RNA, Messenger / metabolism. Thyroid Neoplasms / metabolism

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399756.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hepatocyte Nuclear Factor 1-alpha; 0 / RNA, Messenger; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


10. Lopez-Beltran A, Eble JN, Bostwick DG: Pleomorphic giant cell carcinoma of the prostate. Arch Pathol Lab Med; 2005 May;129(5):683-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic giant cell carcinoma of the prostate.
  • We report the clinical and pathologic features of 2 cases of pleomorphic giant cell carcinoma of the prostate.
  • One case was found at autopsy in a 77-year-old man and was composed of high-grade prostatic adenocarcinoma with prominent anaplastic giant cells.
  • The patient presented with metastases to multiple retroperitoneal lymph nodes, liver, and lumbar vertebrae.
  • The second case occurred in a 45-year-old man who underwent transurethral resection of the prostate and was found to have high-grade prostatic adenocarcinoma with an extensive anaplastic giant cell component.
  • Both regular adenocarcinoma and anaplastic giant tumor cells displayed cytoplasmic immunoreactivity for prostate-specific antigen, prostatic acid phosphatase, and keratin AE1/AE3; in one case, scattered cells were also positive for chromogranin and epithelial membrane antigen.
  • Pleomorphic giant cell carcinoma is a rare variant of prostatic adenocarcinoma with a poor prognosis that should be considered in the differential diagnosis of prostatic pleomorphic tumors.
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Carcinoma, Giant Cell / diagnosis. Carcinoma, Giant Cell / secondary. Diagnosis, Differential. Fatal Outcome. Humans. Liver Neoplasms / secondary. Lumbar Vertebrae / pathology. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Melanoma / diagnosis. Melanoma / secondary. Middle Aged. Retroperitoneal Space

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15859643.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Nakajima A, Takahashi H, Inamori M, Abe Y, Kobayashi N, Kubota K, Yamanaka S: Anaplastic carcinoma of the pancreas producing granulocyte-colony stimulating factor: a case report. J Med Case Rep; 2008;2:391

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic carcinoma of the pancreas producing granulocyte-colony stimulating factor: a case report.
  • INTRODUCTION: The granulocyte-colony stimulating factor-producing tumor was first reported in 1977, however, anaplastic pleomorphic type carcinoma of the pancreas producing granulocyte-colony stimulating factor is still rare.
  • Abdominal computed tomography demonstrated a pancreatic tumor 10 cm in size and multiple low-density areas in the liver.
  • Based on liver biopsy findings, the tumor was classified as an anaplastic pleomorphic-type carcinoma.
  • Immunohistochemical staining showed that pancreatic carcinoma cells were positive for granulocyte-colony stimulating factor.
  • CONCLUSION: This is a rare case report of anaplastic pleomorphic-type carcinoma of the pancreas producing granulocyte-colony stimulating factor and confirmed by immunohistochemistry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 1998 Dec;27(4):357-60 [9855271.001]
  • [Cites] Br J Cancer. 1997;76(12):1661-6 [9413959.001]
  • [Cites] Int J Pancreatol. 1996 Apr;19(2):135-9 [8723556.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1992 Aug;30(8):1548-53 [1279257.001]
  • [Cites] Gan No Rinsho. 1989 Mar;35(4):523-7 [2469806.001]
  • [Cites] Blood. 1977 May;49(5):845-52 [300638.001]
  • [Cites] JOP. 2004 Nov;5(6):512-5 [15536293.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):258-9 [11197273.001]
  • [Cites] JOP. 2008;9(4):493-8 [18648141.001]
  • [Cites] Int J Colorectal Dis. 2008 Jul;23(7):729-31 [18379798.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2007 Feb;104(2):233-8 [17283419.001]
  • [Cites] Hepatogastroenterology. 2006 Nov-Dec;53(72):957-9 [17153462.001]
  • [Cites] Ann Diagn Pathol. 2001 Jun;5(3):129-40 [11436166.001]
  • (PMID = 19091098.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2615780
  •  go-up   go-down


12. Khan N, Oriuchi N, Higuchi T, Endo K: Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control; 2005 Oct;12(4):254-60
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas.
  • BACKGROUND: The goal of posttreatment follow-up for medullary and anaplastic thyroid cancer (MTC and ATC) is the early diagnosis of recurrence or metastases.
  • However, the PET technique is limited by less accurate spatial assignment of small lesions, especially in the lung and liver.
  • [MeSH-major] Carcinoma / radionuclide imaging. Carcinoma, Medullary / radionuclide imaging. Fluorodeoxyglucose F18. Radiopharmaceuticals. Thyroid Neoplasms / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258498.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 45
  •  go-up   go-down


13. Kim KJ, Yim HJ, Kim MJ, Choung RS, Yeon JE, Lee HS, Byun KS, Lee SW, Choi JH, Ryu HS, Lee CH, Hyun JH, Lee ES, Kim YS: [A case of primary small cell neuroendocrine carcinoma of the liver]. Korean J Gastroenterol; 2006 Jul;48(1):37-41
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary small cell neuroendocrine carcinoma of the liver].
  • Small cell neuroendocrine carcinoma is a type of undifferentiated, malignant neuroendocrine tumor.
  • However, carcinomas of the liver with anaplastic characters, which are classified as small-cell carcinomas are extremely rare and only few cases have been reported in the literature.
  • We report an unusual case of primary small cell neuroendocrine carcinoma of the liver in a 67-year-old man.
  • The diagnosis was made by immunohistochemical stains of biopsied specimen from the liver.
  • [MeSH-major] Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Small Cell / diagnosis. Liver Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861880.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


14. Cannizzo E, Sohani AR, Ferry JA, Hochberg EP, Kluk MJ, Dorn ME, Sadowski C, Bucci JJ, Ackerman AM, Longtine JA, Carulli G, Preffer FI: Carcinoma and multiple lymphomas in one patient: establishing the diagnoses and analyzing risk factors. J Hematop; 2009;2(3):163-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma and multiple lymphomas in one patient: establishing the diagnoses and analyzing risk factors.
  • We report the case of a patient who showed the sequential occurrence of four different lymphoid neoplasms together with a squamous cell carcinoma of the lung.
  • Two years later, a PET-CT scan showed a left hilar mass in the lung; biopsy showed a squamous cell carcinoma.
  • After some months, a liver biopsy and a right cervical lymph node biopsy showed a CD30-positive peripheral T cell lymphoma consistent with anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.
  • Flow cytometry and cytogenetic and molecular genetic analysis performed at diagnosis and during the patient's follow-up confirmed the presence of two clonally distinct B cell lymphomas, while the two T cell neoplasms were confirmed to be clonally related.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2002 Nov;100(5 Pt 2):1079-82 [12423812.001]
  • [Cites] J Chemother. 2003 Aug;15(4):406-8 [12962371.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1489-97 [17372278.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):630-6 [11979093.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Jun;17(2):239-42 [9700587.001]
  • [Cites] Leuk Lymphoma. 1999 Mar;33(1-2):161-8 [10194134.001]
  • [Cites] Eur J Haematol. 2000 Aug;65(2):123-7 [10966173.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):997-1005 [11592772.001]
  • [Cites] Rinsho Ketsueki. 1986 Dec;27(12):2313-8 [3573322.001]
  • (PMID = 20309424.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2766444
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Cytogenetics / Diffuse large B cell lymphoma / Follicular lymphoma / Multiple malignancies / Risk factors
  •  go-up   go-down


15. Neumann S: [Effects of different liver diseases on the platelet count in dogs]. Dtsch Tierarztl Wochenschr; 2006 Jun;113(6):224-7
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of different liver diseases on the platelet count in dogs].
  • Changes of the platelet count in liver diseases are described in humans.
  • There are only a few investigations on platelet counts in liver diseases in dogs.
  • The goal of the present study was to investigate the influence of different liver diseases including degeneration, hepatitis and liver tumours, on the platelet count.
  • Platelet counts of 52 dogs with different liver diseases were measured and compared with 52 healthy dogs.
  • The results showed, that dogs with liver degeneration have thrombocytosis in 41% of the cases and a group of dogs with liver tumours (malignant histiocytosis, hepatoma, malignant lymphoma anaplastic sarcoma, cholangiocarcinoma, hepatocellular carcinoma) had thrombocytopenia in 50% of the cases.
  • The statistical comparison of our patients with liver disease and a control group of healthy dogs showed significantly higher platelet counts in cases of liver degeneration (p < 0.0001) and significantly lower platelet counts in cases of liver tumour (p < 0.001).
  • The comparison between the dogs with different liver diseases showed significantly lower platelet counts in dogs with liver tumours when compared to dogs with liver degeneration (p < 0.0001).
  • There was no significant difference between dogs with liver tumours and dogs with hepatitis and between dogs with liver degeneration and dogs with hepatitis.
  • Based on the results of this study the author recommends to assess platelet counts in all dogs with liver disease, especially if liver biopsy is planed.
  • [MeSH-major] Dog Diseases / blood. Liver Diseases / veterinary. Platelet Count / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856607.001).
  • [ISSN] 0341-6593
  • [Journal-full-title] DTW. Deutsche tierärztliche Wochenschrift
  • [ISO-abbreviation] DTW. Dtsch. Tierarztl. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Ligato S, Mandich D, Cartun RW: Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study. Mod Pathol; 2008 May;21(5):626-31
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study.
  • We evaluated the immunocytochemical expression of GPC3 in archival material obtained from fine needle aspiration of hepatic lesions to assess the sensitivity and specificity of this marker in cytological material and its potential diagnostic utility in differentiating hepatocellular carcinoma (HCC) from other primary benign or malignant hepatic tumors and from metastatic lesions in the liver.
  • Forty-nine FNAs of the liver obtained between January 2000 and June 2006 were identified from our cytology files.
  • Cytological diagnoses (confirmed by tissue diagnosis and/or clinical follow-up) included: 7 adenomas, 1 focal nodular hyperplasia (FNH), 24 HCCs, and 17 metastatic tumors.
  • The only case expressing GPC3 was an anaplastic carcinoma with neuroendocrine features of unknown origin.
  • In this study, the sensitivity of GPC3 in the diagnosis of HCC in the cytological material was 83.3%, the specificity 96%, the positive predictive value (PPV) 95% and negative predictive value (NPV) was 85.7%.
  • Immunocytochemical staining for GPC3 in alcohol-fixed FNA material is a highly sensitive and specific method capable of distinguishing HCC from other benign and malignant hepatic lesions and from the great majority of metastatic lesions.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Carcinoma, Hepatocellular / diagnosis. Glypicans / biosynthesis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264086.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans
  •  go-up   go-down


17. Zhou JM, Zhu XF, Liu ZC, Fu LW, Yang XP, Liang YJ, Pan QC: [Antitumor and anti-angiogenic effects of manumycin on human hepatocellular carcinoma HepG2 xenografts in nude mice]. Ai Zheng; 2005 Aug;24(8):935-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Antitumor and anti-angiogenic effects of manumycin on human hepatocellular carcinoma HepG2 xenografts in nude mice].
  • BACKGROUND & OBJECTIVE: Farnesyl-transferase inhibitor manumycin has in vitro and in vivo antitumor effects on pancreatic cancer, colon cancer, and anaplastic thyroid carcinoma.
  • Our previous experiments showed that manumycin could inhibit proliferation pathway and survival pathway in human hepatocellular carcinoma HepG2 cells in vitro.
  • CONCLUSIONS: Manumycin could inhibit the growth of human hepatocellular carcinoma HepG2 xenografts in nude mice.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Antineoplastic Agents / pharmacology. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Polyenes / pharmacology. Polyunsaturated Alkamides / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Dose-Response Relationship, Drug. Female. Fibroblast Growth Factor 2 / metabolism. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Microcirculation / drug effects. Neoplasm Transplantation. Neovascularization, Pathologic. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Random Allocation. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086869.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Polyenes; 0 / Polyunsaturated Alkamides; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; 52665-74-4 / manumycin
  •  go-up   go-down


18. Patnaik AK, Lieberman PH, Erlandson RA, Antonescu C: Hepatobiliary neuroendocrine carcinoma in cats: a clinicopathologic, immunohistochemical, and ultrastructural study of 17 cases. Vet Pathol; 2005 May;42(3):331-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatobiliary neuroendocrine carcinoma in cats: a clinicopathologic, immunohistochemical, and ultrastructural study of 17 cases.
  • Hepatobiliary neuroendocrine carcinoma was diagnosed in 17 cats in a period of 10 years.
  • Seven tumors were of intrahepatic origin, one of which was a composite containing components of epithelial and neuroendocrine carcinoma.
  • Hepatomegaly, anorexia, weight loss, and vomiting were the most common clinical signs observed in the cats with hepatic neuroendocrine carcinoma.
  • The cats with extrahepatic neuroendocrine carcinoma showed these signs plus icterus (5/9) and high concentrations of hepatic enzymes.
  • Histologically, the hepatic neuroendocrine carcinomas had two patterns, one with acinar structures separated by vascular stroma lined by cuboidal or columnar cells and the other solid with groups of anaplastic cells separated by vascular stroma.
  • The composite tumor consisted of both bile duct carcinoma and neuroendocrine carcinoma.
  • The extrahepatic neuroendocrine carcinomas and the gallbladder neuroendocrine carcinoma were characterized by solid sheets or groups of round to oval cells with vascular or fibrovascular stroma.
  • Immunohistochemical examination of 10 of the neuroendocrine carcinomas revealed that all 10 stained with neuron-specific enolase; one bile duct carcinoma and the gallbladder carcinoma stained with chromogranin; four of five bile duct carcinomas and the gall bladder carcinoma stained with synaptophysin; and one bile duct carcinoma stained with gastrin.
  • One cat with hepatic carcinoma had duodenal ulcer; in this cat, ultrastructural studies showed neurosecretory granules leading to the diagnosis of Zollinger-Ellison syndrome.
  • [MeSH-major] Biliary Tract Neoplasms / veterinary. Carcinoma, Neuroendocrine / veterinary. Cat Diseases / pathology. Liver Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15872379.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kalac M, Ostojić S, Gasparov S, Planinc-Peraica A, Dominis M, Jaksić B: [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report]. Lijec Vjesn; 2006 Mar-Apr;128(3-4):76-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report].
  • Hepatosplenic T-cell lymphoma (HSTCL) is a rare form of extranodal non-Hodgkin lymphoma derived from cytotoxic T-cells, usually manifesting by sinusoidal infiltration of spleen, liver and bone marrow.
  • In 1997 World Health Organization classified malignant lymphomas and placed HSTCL among peripheral T-cell neoplasms.
  • Upon the completion of the 6th course of therapy he was diagnosed with lung anaplastic microcellular carcinoma and was treated with 3 course of PE therapy (cisplatin, etoposide).
  • [MeSH-major] Carcinoma, Small Cell / pathology. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Lymphoma, T-Cell / pathology. Neoplasms, Second Primary / pathology. Splenic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16808095.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


20. Liang HH, Wu CH, Tam KW, Chai CY, Lin SE, Chen SC: Thyroid metastasis in a patient with hepatocellular carcinoma: case report and review of literature. World J Surg Oncol; 2007;5:144
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid metastasis in a patient with hepatocellular carcinoma: case report and review of literature.
  • Although lung, renal, and breast cancer are probably the most common primary sites, a number of cancers have been reported to metastasize to the thyroid synchronously with diagnosis of primary tumor or years after apparently curative treatment.
  • CASE PRESENTATION: We report a rare case of a hepatocellular carcinoma metasatic to the thyroid.
  • The patient presented seven months after original diagnosis and treatment with hepatic lobectomy with multiple neck lesions producing a mass effect on the trachea and bilateral lymphadenopathy.
  • Fine-needle aspiration revealed highly anaplastic carcinoma, and immunohistochemistry confirmed hepatocellular carcinoma.
  • The patient received total thyroidectomy as palliative therapy because of the presence of multiple recurrent lesions in the liver.
  • In cases where cytology or histology is not diagnostic, immunohistochemistry may be definitive in making the diagnosis.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma, Hepatocellular / secondary. Liver Neoplasms / pathology. Thyroid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Clin Oncol. 2004 Dec;9(6):515-9 [15616884.001]
  • [Cites] Ann Surg. 1960 Apr;151:551-61 [13820008.001]
  • [Cites] Thyroid. 1998 Feb;8(2):149-53 [9510123.001]
  • [Cites] Int J Clin Oncol. 2007 Feb;12(1):63-7 [17380445.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):574-8 [9028370.001]
  • [Cites] Eur J Surg Oncol. 2004 Aug;30(6):583-8 [15256229.001]
  • [Cites] Radiat Med. 2001 Jan-Feb;19(1):43-6 [11305618.001]
  • [Cites] J Formos Med Assoc. 2001 Feb;100(2):106-12 [11393097.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118(6):911-21 [12472285.001]
  • [Cites] J Am Coll Surg. 2005 Feb;200(2):203-7 [15664095.001]
  • [Cites] Arch Pathol Lab Med. 1998 Jan;122(1):37-41 [9448014.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):236-41 [15670202.001]
  • (PMID = 18157914.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2246133
  •  go-up   go-down


21. Wakshlag JJ, McNeill CJ, Antonyak MA, Boehm JE, Fuji R, Balkman CE, Zgola M, Cerione RA, Page RL: Expression and activity of transglutaminase II in spontaneous tumours of dogs and cats. J Comp Pathol; 2006 Feb-Apr;134(2-3):202-10
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bladder, liver and adrenal gland exhibited prominent expression of TGase II while other tissues, including mammary gland, displayed limited expression and activity.
  • The pattern of expression was not related to the classification of mammary carcinoma (solid, tubulopapillary, complex or anaplastic), except that two anaplastic canine mammary carcinomas showed prominent TGase II expression.
  • Two canine mammary carcinoma cell lines showed prominent TGase expression, and when the TGase activity was inhibited, the cells became more sensitive to doxorubicin-induced cell death.
  • The pro-survival effect of TGase II in canine mammary carcinoma cell lines was similar to that previously reported in humans patients.
  • [MeSH-major] Carcinoma / veterinary. GTP-Binding Proteins / metabolism. Mammary Glands, Animal / enzymology. Mammary Neoplasms, Animal / enzymology. Transglutaminases / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615935.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM61762
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; EC 2.3.2.- / transglutaminase 2; EC 2.3.2.13 / Transglutaminases; EC 3.6.1.- / GTP-Binding Proteins
  •  go-up   go-down


22. Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R: Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol; 2010 Nov 20;28(33):4953-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Grade 3 or higher liver function abnormalities were observed in nine patients (11.8%).
  • [MeSH-major] Benzoquinones / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / therapeutic use. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20940188.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 4GY0AVT3L4 / tanespimycin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC4676802
  •  go-up   go-down


23. Hornick JL, Dal Cin P, Fletcher CD: Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma. Am J Surg Pathol; 2009 Apr;33(4):542-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INI1 (hSNF5/SMARCB1), a member of the SWI/SNF chromatin remodeling complex located on chromosome 22q11.2, is deleted or/or mutated in strictly defined malignant rhabdoid tumors (MRT) of infancy.
  • However, very few cases of ES have been studied, and INI1 expression in other epithelioid malignant neoplasms has not been examined systematically.
  • We evaluated 350 tumors: 136 ES, including 64 conventional ("distal") ES, 64 proximal-type ES, and 8 with hybrid features of conventional and proximal-type ES; 54 metastatic carcinomas (22 from lung, 6 breast, 6 stomach, 5 colorectum, 5 kidney, 5 prostate, 5 pancreas); 12 metastatic testicular embryonal carcinomas; 20 metastatic melanomas; 20 epithelioid mesotheliomas; 20 epithelioid angiosarcomas; 10 epithelioid hemangioendotheliomas; 24 epithelioid malignant peripheral nerve sheath tumors (MPNST); 22 myoepithelial carcinomas of soft tissue; 7 anaplastic large cell lymphomas; 5 histiocytic sarcomas; and 10 control MRT of infancy (4 brain, 3 liver, 2 soft tissue, 1 kidney).
  • Immunostaining for INI1 can be used to confirm the diagnosis of ES in the appropriate context.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Carcinoma, Embryonal / metabolism. Carcinoma, Embryonal / secondary. Female. Humans. Immunohistochemistry / methods. Infant. Male

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033866.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


24. Shor S, Helfand SC, Gorman E, Löhr CV: Diagnostic exercise: epithelioid hemangiosarcoma mimicking metastatic prostatic neoplasia in a dog. Vet Pathol; 2009 May;46(3):548-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical examination revealed blepharospasm and hyphema, with clear discharge from the right eye; a firm mass in an enlarged right testicle; a mass in the irregularly enlarged prostate; and nodules in the left kidney, liver, and spleen detected by abdominal sonography.
  • Cytologic evaluation of fine needle aspirates from the prostate, testis, and kidney comprised large, clustered or individualized, anaplastic cells that lacked convincing tissue differentiation.
  • Necropsy examination revealed an irregularly enlarged prostate with dark tan to red zones and multiple, discrete, beige to dark red nodules that ranged from 0.5 to 6 cm in diameter in the lung, liver, left kidney, right testis, colon wall, stomach wall, and brain.
  • On histologic examination, discrete nests of anaplastic carcinoma-like tumor cells were found in sections of all affected organs.
  • The diagnosis was metastatic epithelioid hemangiosarcoma, primary site unknown.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176508.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hussain T, Salamat A, Farooq MA, Hassan F, Hafeez M: Indications for endoscopic ultrasound and diagnosis on fine-needle aspiration and cytology. J Coll Physicians Surg Pak; 2009 Apr;19(4):223-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications for endoscopic ultrasound and diagnosis on fine-needle aspiration and cytology.
  • OBJECTIVE: To determine common indications for requesting Endoscopic Ultrasound (EUS) and to describe the diagnosis made after endoscopic ultrasound/Fine-Needle Aspiration and Cytology (FNAC) during two years at a tertiary gastrointestinal unit.
  • An on-site cytopathologist made the provisional cytopathological diagnosis.
  • Major indications for referral were lymphadenopathy in 92 (49%), suspected growth pancreas in 57 (28%), growth of stomach in 20 (11%) and a heterogeneous group included esophageal, liver, retroperitoneal masses, rectal and other pathologies.
  • Final diagnosis out of 67 FNAC/histopathology of lymph nodes were tuberculosis in 26 and malignant lesions in 23.
  • These included metastatic adenocarcinoma in 8, lymphoproliferative disorder in 7, metastatic squamous cell carcinoma in 5, small cell carcinoma in 2 and anaplastic in 1.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endosonography / methods. Lymphatic Diseases / diagnosis. Pancreatic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis. Tuberculosis, Lymph Node / diagnosis
  • [MeSH-minor] Abdomen. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle / methods. Cross-Sectional Studies. Diagnosis, Differential. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Lymphatic Metastasis / ultrasonography. Male. Mediastinum. Middle Aged. Neoplasm Staging. Pancreatitis, Chronic / diagnosis. Pancreatitis, Chronic / pathology. Pancreatitis, Chronic / ultrasonography. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356336.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down






Advertisement